Patents Examined by David M Shim
-
Patent number: 11975008Abstract: Pharmaceutical compositions comprising filgotinib maleate Form I characterized by an XRPD pattern substantially the same as shown in FIG. 1 and uses thereof are described herein.Type: GrantFiled: February 26, 2021Date of Patent: May 7, 2024Assignee: GALAPAGOS NVInventors: David Alonzo, Bei Li, Dimitrios Stefanidis
-
Patent number: 11964982Abstract: Compounds for treating cancer and, particularly, to compounds that are 5-(3-substituted phenyl)-pyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione analogues and their use as anticancer agents.Type: GrantFiled: November 10, 2023Date of Patent: April 23, 2024Assignee: KING FAISAL UNIVERSITYInventors: Katharigatta N. Venugopala, Pran Kishore Deb, Vinuta Kamat, Rangappa Santosh, Boja Poojary, Manohar S. Kugaji, Vijay M. Kumbar, Mohamed A. Morsy, Bandar Aldhubiab, Mahesh Attimarad, Anroop B. Nair, Nagaraja Sreeharsha
-
Patent number: 11931343Abstract: Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.Type: GrantFiled: August 26, 2019Date of Patent: March 19, 2024Assignee: Arcus Biosciences, Inc.Inventors: Joel Beatty, Laurent Pierre Paul Debien, Samuel Lawrie Drew, Jeremy Fournier, Rebecca Louise Grange, Steven Donald Jacob, Jenna Leigh Jeffrey, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Debashis Mandal, Jay Patrick Powers, Anh Thu Tran, Rhiannon Thomas-Tran, Xuelei Yan
-
Patent number: 11925641Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.Type: GrantFiled: March 29, 2021Date of Patent: March 12, 2024Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem LtdInventors: Yinon Ben-Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph P. Vacca, Dansu Li
-
Patent number: 11925640Abstract: Provided herein are methods and materials for improving arteriovenous fistula (AVF) maturation and/or maintaining AVF functionality. For example, methods and materials for using one or more senolytic agents to improve AVF maturation, to maintain AVF functionality, and/or to maintain the patency of an AVF are provided. Methods and materials for using one or more senolytic agents to maintain functionality and/or patency of a venous graft (e.g., a venous graft that bypasses an occluded artery) also are provided.Type: GrantFiled: June 21, 2019Date of Patent: March 12, 2024Assignee: Mayo Foundation for Medical Education and ResearchInventors: Karl A. Nath, James L. Kirkland, Tamar Tchkonia
-
Patent number: 11918568Abstract: The present invention relates to a novel fused ring compound having urea structure that exhibits excellent NAMPT activating effect, and a method using the same for treating/preventing metabolic disorder, cardiovascular and kidney disease, mitochondrial disease, neurodegenerative disease, ocular disease, and muscle wasting disorder. The present invention provides a compound represented by following formula (I) or a pharmacologically acceptable salt: Formula (I) wherein A, B, R, R2 and R3 represent the same meanings as in the claims.Type: GrantFiled: July 3, 2019Date of Patent: March 5, 2024Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Tsuyoshi Nakamura, Mayuko Akiu, Takashi Tsuji, Jun Tanaka, Koji Terayama, Mika Yokoyama, Anthony B. Pinkerton, Edward Hampton Sessions
-
Patent number: 11866436Abstract: Provided are a compound of the formula: (5-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethoxy)benzo[c][2,6]naphthyridine-8-carboxylic acid) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the above compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.Type: GrantFiled: April 14, 2023Date of Patent: January 9, 2024Assignee: Cambridge Enterprise LimitedInventors: Marko Juhana Hyvonen, Paul Brear, David Robert Spring, Paul Glossop
-
Patent number: 11851436Abstract: The present disclosure relates to a compound of Formula (0): a stereoisomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof. The present disclosure also relates to uses of the compound.Type: GrantFiled: June 3, 2022Date of Patent: December 26, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATEInventors: Philip Reigan, Kimberly A. Casalvieri
-
Patent number: 11827618Abstract: The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms, such as tablets, made by these processes. Additionally, embodiments of the present invention provide tablets including 25 mg, 50 mg, 100 mg, or 200 mg free base equivalent of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate.Type: GrantFiled: April 14, 2023Date of Patent: November 28, 2023Inventors: Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
-
Patent number: 11814363Abstract: This invention provides stable, highly crystalline forms of Complement factor D inhibitors Compound 1 for advantageous therapeutic pharmaceutical efficacy and dosage form stability.Type: GrantFiled: September 6, 2019Date of Patent: November 14, 2023Assignee: Achillion Pharmaceuticals, Inc.Inventors: Avinash Phadke, Akihiro Hashimoto, Wei Ma, Lee M. Katrincic
-
Patent number: 11814382Abstract: Provided are crystal forms A, B, C and D of a compound of formula (I), and application of the crystal forms in the preparation of drugs for treating ASK1-related diseases.Type: GrantFiled: July 19, 2019Date of Patent: November 14, 2023Assignee: FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD.Inventors: Shengbin Zhang, Ning Li, Tao Yu, Yusheng Fu, Jiahu Wu, Chengde Wu
-
Patent number: 11801234Abstract: This application describes methods of inhibiting APOL1 and treating APOL1-mediated kidney diseases comprising administering Compound I and/or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I and/or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 5, 2021Date of Patent: October 31, 2023Assignee: Vertex Pharmaceuticals IncorporatedInventors: Navita Mallalieu, Ifeatu Egbuna, Brian J. Hare, Alexander Wolfgang Krug, Shu-Pei Wu
-
Patent number: 11801236Abstract: The present invention provides a method for improving the stability of pramipexole or its salt preparation, and further provides a pramipexole hydrochloride oral liquid with excellent stability and oral absorption effect. The pramipexole hydrochloride oral liquid of the present invention is prepared through a simple process, and shows bioequivalence with the tablet containing pramipexole hydrochloride. The invention perfectly realizes multi-dose administration of pramipexole hydrochloride and improves the compliance and accessibility of medication for patients.Type: GrantFiled: January 8, 2021Date of Patent: October 31, 2023Assignees: CHANGZHOU NO.4 PHARMACEUTICAL FACTORY CO. LTD, BEIJING DO-PHARMA TECH CO. LTDInventors: Xinhua Fan, Yanyuan Zhang, Yun He, Pengfei Li, Xiang Zhang, Longhao Wu, Peng Peng, Sujing Zhuang, Li Xiao, Yongrui Tu
-
Patent number: 11795165Abstract: Compounds of formula (I?), wherein A, R1, R2, T1, T2, T3, T4, L, W, Z, R??, m and n have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.Type: GrantFiled: August 22, 2019Date of Patent: October 24, 2023Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri, Grant Wishart, Paul Rakesh
-
Patent number: 11780804Abstract: Provided herein are processes for purifying TCH in a feed stream, such as an adiponitrile process stream. The processes include a first separating step of separating the adiponitrile process stream to form a first overhead stream comprising low-boiling components and high-boiling components and a first bottoms stream comprising high-boiling components. The processes also include a second separating step of separating the first overhead stream in one or more distillation columns to form a lights stream comprising low-boiling components, a heavies stream comprising high-boiling components, and a TCH stream.Type: GrantFiled: May 21, 2020Date of Patent: October 10, 2023Assignee: Ascend Performance Materials Operations LLCInventors: Sanjay Dube, Darrick Elmore
-
Patent number: 11780832Abstract: Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with ?-lactamase inhibitors and/or other antibiotics (including ?-lactam and non-?-lactam antibiotics) in the treatment or prevention of bacterial infections.Type: GrantFiled: March 29, 2022Date of Patent: October 10, 2023Assignee: FEDORA PHARMACEUTICALS INC.Inventors: Renata Jankowska, Sameeh M. Salama, Samarendra N. Maiti
-
Patent number: 11773092Abstract: Pyrido[3,4-b]indol-1-one compounds useful as antibacterial agents having the formula I: or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof, wherein R1, R2, R3, and R4 are as described herein. These compounds are effective in treating a bacterial infection in a patient.Type: GrantFiled: March 27, 2023Date of Patent: October 3, 2023Assignee: KING FAISAL UNIVERSITYInventors: Michelyne Haroun, Christophe Tratrat
-
Patent number: 11746110Abstract: Disclosed are alkynyl (hetero) aromatic ring compounds that inhibit protein tyrosine kinases, pharmaceutical compositions comprising same, preparations therefor and uses thereof. Specifically, disclosed are an alkynyl (hetero) aromatic ring compound represented by formula (I), and a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a crystal form, a prodrug or an isotope variant thereof. The disclosed compounds may be used in the treatment and/or prevention of diseases associated with protein tyrosine kinase, such as in preventing tumors.Type: GrantFiled: July 16, 2019Date of Patent: September 5, 2023Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Qingfeng Xing, Yixin Ai
-
Patent number: 11739079Abstract: HM30181 (shown below) can be used to improve absorption of cancer chemotherapy drugs, such as paclitaxel. Herein are described various polymorphisms of HM30181, in particular polymorphism C, as well as their physical properties and methods for their preparation and characterization.Type: GrantFiled: October 28, 2021Date of Patent: August 29, 2023Assignee: ATHENEX R&D. LLCInventors: Sameer Urgaonkar, Michael P. Smolinski, Johnson Yiu-Nam Lau
-
Patent number: 11737995Abstract: Methods for treating or preventing kidney diseases and fibrosis, such as chronic kidney disease (CKD), kidney fibrosis, heart fibrosis, uterine fibrosis, and cystic fibrosis, with compounds of Formulae (I), (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof.Type: GrantFiled: January 24, 2022Date of Patent: August 29, 2023Assignee: Espervita Therapeutics, Inc.Inventors: Daniela Carmen Oniciu, Gregory R. Steinberg, Spencer Heaton, Roger Schofield Newton, James Stuart Vincent Lally, Jaya Gautam